Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $12.3333.

Several equities analysts have issued reports on the company. Lake Street Capital lifted their target price on Evaxion A/S from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Jones Trading upgraded shares of Evaxion A/S to a “strong-buy” rating in a research note on Wednesday, October 29th. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 14th. Finally, Edward Jones initiated coverage on Evaxion A/S in a research report on Thursday, October 30th. They set a “buy” rating and a $10.00 price target on the stock.

Institutional Investors Weigh In On Evaxion A/S

An institutional investor recently raised its position in Evaxion A/S stock. Merck & Co. Inc. increased its stake in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) by 123.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,214,126 shares of the company’s stock after purchasing an additional 671,847 shares during the period. Evaxion A/S accounts for about 1.4% of Merck & Co. Inc.’s portfolio, making the stock its 6th largest position. Merck & Co. Inc. owned about 86.54% of Evaxion A/S worth $2,246,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Trading Up 2.1%

Shares of NASDAQ EVAX opened at $4.83 on Friday. The stock has a market capitalization of $40.29 million, a PE ratio of -12.39 and a beta of 0.28. Evaxion A/S has a 12-month low of $1.20 and a 12-month high of $12.15. The stock’s fifty day simple moving average is $5.72 and its two-hundred day simple moving average is $4.15.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.